-
Je něco špatně v tomto záznamu ?
The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering
R. Pytlík, D. Stehlík, T. Soukup, M. Kalbacova, F. Rypacek, T. Trč, K. Mulinkova, P. Michnova, L. Kideryová, J. Živný, P. Jr. Klener, R. Veselá, M. Trněný, P. Klener
Jazyk angličtina Země Velká Británie
Typ dokumentu hodnotící studie, práce podpořená grantem
Grantová podpora
NR9182
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
- MeSH
- buněčná diferenciace fyziologie MeSH
- buněčné kultury MeSH
- buňky stromatu cytologie fyziologie MeSH
- cytokiny metabolismus MeSH
- dospělí MeSH
- kosti a kostní tkáň fyziologie MeSH
- kultivační média chemie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mezenchymální kmenové buňky cytologie fyziologie MeSH
- mezibuněčné signální peptidy a proteiny metabolismus MeSH
- mladý dospělý MeSH
- multipotentní kmenové buňky cytologie fyziologie MeSH
- myši inbrední NOD MeSH
- myši MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- tkáňové inženýrství metody MeSH
- transplantace mezenchymálních kmenových buněk MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- myši MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- hodnotící studie MeSH
- práce podpořená grantem MeSH
Clinical application of human multipotent mesenchymal stromal cells (hMSCs) requires their expansion to be safe and rapid. We aimed to develop an expansion protocol which would avoid xenogeneic proteins, including fetal calf serum (FCS), and which would shorten the cultivation time and avoid multiple passaging. First, we have compared research-grade alpha-MEM medium with clinical grade CellGro for Hematopoietic Cells' Medium. When FCS was used for supplementation and non-adherent cells were discarded, both media were comparable. Both media were comparable also when pooled human serum (hS) was used instead of FCS, but the numbers of hMSCs were lower when non-adherent cells were discarded. However, significantly more hMSCs were obtained both in alpha-MEM and in CellGro supplemented with hS when the non-adherent cells were left in the culture. Furthermore, addition of recombinant cytokines and other supplements (EGF, PDGF-BB, M-CSF, FGF-2, dexamethasone, insulin and ascorbic acid) to the CellGro co-culture system with hS led to 40-fold increase of hMSCs' yield after two weeks of cultivation compared to alpha-MEM with FCS. The hMSCs expanded in the described co-culture system retain their osteogenic, adipogenic and chondrogenic differentiation potential in vitro and produce bone-like mineralized tissue when propagated on 3D polylactide scaffolds in immunodeficient mice. Our protocol thus allows for very effective one-step, xenogeneic protein-free expansion of hMSCs, which can be easily transferred into good manufacturing practice (GMP) conditions for large-scale, clinical-grade production of hMSCs for purposes of tissue engineering.
- 000
- 03988naa 2200661 a 4500
- 001
- bmc11009340
- 003
- CZ-PrNML
- 005
- 20140404131515.0
- 008
- 110509s2009 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pytlík, Robert, $d 1967- $7 xx0061345
- 245 14
- $a The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering / $c R. Pytlík, D. Stehlík, T. Soukup, M. Kalbacova, F. Rypacek, T. Trč, K. Mulinkova, P. Michnova, L. Kideryová, J. Živný, P. Jr. Klener, R. Veselá, M. Trněný, P. Klener
- 314 __
- $a First Department of Medicine, Charles University, Prague, Czech Republic. pytlikr@seznam.cz
- 520 9_
- $a Clinical application of human multipotent mesenchymal stromal cells (hMSCs) requires their expansion to be safe and rapid. We aimed to develop an expansion protocol which would avoid xenogeneic proteins, including fetal calf serum (FCS), and which would shorten the cultivation time and avoid multiple passaging. First, we have compared research-grade alpha-MEM medium with clinical grade CellGro for Hematopoietic Cells' Medium. When FCS was used for supplementation and non-adherent cells were discarded, both media were comparable. Both media were comparable also when pooled human serum (hS) was used instead of FCS, but the numbers of hMSCs were lower when non-adherent cells were discarded. However, significantly more hMSCs were obtained both in alpha-MEM and in CellGro supplemented with hS when the non-adherent cells were left in the culture. Furthermore, addition of recombinant cytokines and other supplements (EGF, PDGF-BB, M-CSF, FGF-2, dexamethasone, insulin and ascorbic acid) to the CellGro co-culture system with hS led to 40-fold increase of hMSCs' yield after two weeks of cultivation compared to alpha-MEM with FCS. The hMSCs expanded in the described co-culture system retain their osteogenic, adipogenic and chondrogenic differentiation potential in vitro and produce bone-like mineralized tissue when propagated on 3D polylactide scaffolds in immunodeficient mice. Our protocol thus allows for very effective one-step, xenogeneic protein-free expansion of hMSCs, which can be easily transferred into good manufacturing practice (GMP) conditions for large-scale, clinical-grade production of hMSCs for purposes of tissue engineering.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kosti a kostní tkáň $x fyziologie $7 D001842
- 650 _2
- $a buněčné kultury $7 D018929
- 650 _2
- $a buněčná diferenciace $x fyziologie $7 D002454
- 650 _2
- $a kultivační média $x chemie $7 D003470
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mezibuněčné signální peptidy a proteiny $x metabolismus $7 D036341
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a transplantace mezenchymálních kmenových buněk $7 D045164
- 650 _2
- $a mezenchymální kmenové buňky $x cytologie $x fyziologie $7 D059630
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední NOD $7 D016688
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multipotentní kmenové buňky $x cytologie $x fyziologie $7 D039902
- 650 _2
- $a buňky stromatu $x cytologie $x fyziologie $7 D017154
- 650 _2
- $a tkáňové inženýrství $x metody $7 D023822
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a hodnotící studie $7 D023362
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Stehlík, David $7 xx0138007
- 700 1_
- $a Soukup, Tomáš
- 700 1_
- $a Hubálek Kalbáčová, Marie $7 xx0119193
- 700 1_
- $a Rypáček, František, $d 1947- $7 jk01103352
- 700 1_
- $a Trč, Tomáš, $d 1955- $7 nlk19990073953
- 700 1_
- $a Mulinkova, Katarina
- 700 1_
- $a Michnova, Petra
- 700 1_
- $a Kideryová, Linda $7 xx0138010
- 700 1_
- $a Živný, Jan $7 xx0115576
- 700 1_
- $a Klener, Pavel, $d 1975- $7 xx0105452
- 700 1#
- $a Veselá, Romana. $7 _AN046823
- 700 1_
- $a Trněný, Marek, $d 1960- $7 nlk20000083659
- 700 1_
- $a Klener, Pavel, $d 1937- $7 jk01060408
- 773 0_
- $t Biomaterials $w MED00000753 $g Roč. 30, č. 20 (2009), s. 3415-3427
- 910 __
- $a ABA008 $b x $y 6 $z 0
- 990 __
- $a 20110513104704 $b ABA008
- 991 __
- $a 20140404131556 $b ABA008
- 999 __
- $a ok $b bmc $g 838957 $s 702725
- BAS __
- $a 3
- BMC __
- $a 2009 $b 30 $c 20 $d 3415-3427 $m Biomaterials $n Biomaterials $x MED00000753
- GRA __
- $a NR9182 $p MZ0
- LZP __
- $a 2011-2B09/lmme